Julian Baker’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Julian Baker’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-969,727	Closed	-$110M	–	118
2022 Q4	$110M	Hold	969,727	–	–	0.66%	14
2022 Q3	$60M	Sell	969,727 -178,777	-16%	-$12.5M	0.39%	24
2022 Q2	$91.6M	Buy	1,148,504 +249,662	+28%	+$23.6M	0.52%	15
2022 Q1	$94.6M	Buy	898,842 +299,732	+50%	+$29.2M	0.54%	15
2021 Q4	$64.6M	Hold	599,110	–	–	0.31%	29
2021 Q3	$65.6M	Hold	599,110	–	–	0.29%	30
2021 Q2	$56.1M	Hold	599,110	–	–	0.25%	36
2021 Q1	$55.1M	Hold	599,110	–	–	0.24%	35
2020 Q4	$43.8M	Sell	599,110 -67,390	-10%	-$5.01M	0.17%	38
2020 Q3	$51.8M	Buy	666,500 +466,500	+233%	+$32.1M	0.21%	30
2020 Q2	$11.1M	Hold	200,000	–	–	0.05%	58
2020 Q1	$5.92M	Buy	+200,000	New	+$6.77M	0.04%	62

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Julian Baker's HZNP Position: Q1 2023 in Review

Julian Baker sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 969,727 shares — an estimated $110M sold.

Julian Baker first reported a position in HZNP in Q1 2020 and held it in 12 quarters. The position peaked at $110M in Q4 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

Julian Baker reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Julian Baker sold 969,727 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $110M.
Julian Baker first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2020 and held it in 12 quarters.
Julian Baker's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $110M in Q4 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on Baker Bros. Advisors's 13F filing for Q1 2023, filed 15 May 2023.